Skip to main content
. 2021 Jun 1;2021:5579904. doi: 10.1155/2021/5579904

Table 1.

List of components of the MSC-derived exosome molecular cargo to regulate cardiac repairment published in the recent 5 years.

Diseases Component Type of MSCs Target cell Function Reference
Cardiac preservation
Mouse MI miR-214 ADRC CM ADRC-derived exosomes inhibited cardiomyocyte cell damage under hypoxia in vitro, decreased infarcted size, and improved cardiac function through miR-214-regulated clathrin endocytosis. [96]
Mouse MI miR-125b-5p HcBMSCs CM Exosomes from hypoxia-conditioned BMSCs can facilitate cardiac repair and ameliorate CM apoptosis through suppressing the expression of the proapoptotic genes p53 and BAK1. [79]
Mouse MI miR-125b BMSCs NMCM MSC-derived exosomes protect NMCM from hypoxia and serum deprivation-induced autophagic flux, decreased infarct size, and improved cardiac function via miR-125b-mediated p53-Bnip3 signaling. [69]
Mouse MI miR-22 BMSCs NRCMs Exosomes from ischemic preconditioned BMSCs resulted in antiapoptotic effect on CMs due to ischemia by targeting Mecp2 and displayed reduced cardiac fibrosis. [78]
Mouse I/R miR-25-3p BMSCs CM BMSC-derived exosomes protected CMs against oxygen-glucose deprivation-induced apoptosis by directly targeting the proapoptotic genes (FASL and PTEN) and EZH2 to confer cardioprotective effects and suppress inflammation post-I/R injury. [70]
Mouse I/R miR-221/miR-222 ADSCs H9C2 ADSC-derived exosomes protect H9C2 from H2O2-induced injury and repair cardiac I/R injury via the miR-221/miR-222/PUMA/ETS-1 pathway. [97]
Mouse I/R miR-221/222 ADSCs H9C2 ADSC-CM attenuates cardiac apoptosis and fibrosis I/R-induced cardiac injury via the microRNA-221/222/PUMA/ETS-1 pathway. [72]
Rat MI miR-19a hUC-MSCs H9C2 Exosomes secreted by hUC-MSCs protected H9C2 by miR-19a/SOX6-mediated AKT activation and JNK3/caspase-3 inhibition. [98]
Rat MI miR-126 ADSCs H9C2 miR-126-enhanced ADSC-exosomes prevented myocardial damage by inhibiting apoptosis, inflammation, and fibrosis and increasing angiogenesis. [74]
Rat MI miR-146a ADSCs H9C2 miR-146a containing exosomes had more effect than the normal exosome treatment group on the suppression of AMI-induced apoptosis, inflammatory response, and fibrosis in an AMI rat model through interacting with the 3′-untranslated region of EGR1. [71]
Rat MI miR-210 BMSCs NRCM miR-210-overexpressing MSC exosomes exerted myocyte protection by targeting AIFM3 to inhibit NRCM apoptosis and reduce infarct size and improve heart function in the rat MI model. [75]
Rat MI miR-19a BMSCs NRCM GATA-4-overexpressing MSC-derived exosomes contributed to increased CM survival, reduced CM apoptosis, and preserved mitochondrial membrane potential in CM under a hypoxic environment by targeting PTEN to activate the Akt and ERK signaling. [43]
Rat MI miR-338 BMSCs H9C2 Exosomes secreted from BMSCs transfected with miR-338 mimic decreased the apoptosis of H9C2 and improved cardiac function by regulating the MAP3K2/JNK signaling pathway. [77]
Rat MI miR-133 BMSCs NRCM miR-133-overexpressing BMSC-derived exosomes inhibited hypoxia-induced NRCM apoptosis and repressed inflammatory level and the infarct size by targeting snail 1. [76]
Rat MI miR-29 and miR-24 BMSCs H9C2 BMSC-derived exosomes enriched with miR-29 and miR-24 enhanced cardiac repair by promoting CM proliferation, reducing apoptosis induced by H2O2, and inhibiting fibrosis of fibroblast cell induced by TGF-β. [17]
Rat MI miR-21 EnMSCs NRCM EnMSCs showed superior cardioprotective effects through antiapoptotic and angiogenic effects by enhancing cell survival through the miR-21/PTEN/Akt pathway. [73]
Rat MI Circular RNA 0001273 hUC-MSCs H9C2 Circular RNA 0001273 in exosomes of hUC-MSCs inhibited H9C2 apoptosis and promote MI repair. [81]
Rat MI lncRNA KLF3-AS1 MSCs H9C2 Exosomes secreted from human MSCs inhibited H9C2 pyroptosis and attenuated MI progression through the lncRNA KLF3-AS1/miR-138-5p/Sirt1 pathway. [80]
Rat MI Sfrp2 hUC-MSCs H9C2 TIMP2-modified hUC-MSC-derived exosomes can inhibit H2O2-induced H9C2 apoptosis and alleviate MI-induced oxidative stress. [86]
Vitro model miR-144 BMSCs H9C2 BMSC-derived exosomes ameliorated CM apoptosis in hypoxic conditions by delivering miR-144 to recipient cells by targeting the PTEN/AKT pathway. [99]
Vitro model miR-486-5p BMSCs H9C2 miR-486-5p carried by BMSC-derived exosomes promoted the H9C2 proliferation and rescued H9C2 cells from hypoxia/reoxygenation-induced apoptosis by suppressing PTEN expression and activating the PI3K/AKT signaling pathway. [100]
Vitro model lncRNA-NEAT1 hAD-MSCs hiPSC-derived CM Exosomes obtained from MIF-pretreated hAD-MSCs exhibited a protective effect on CM cells from hiPSC differentiation through the lncRNA-NEAT1/miR-142-3p/FOXO1 pathway. [101]
Enhanced angiogenesis
Mouse MI miR-132 BMSCs HUVEC BMSC-derived exosomes can both increase tube formation of HUVEC by targeting RASA1 and enhance the neovascularization in the peri-infarct zone. [82]
Mouse MI miR-210 BMSCs HUVEC miR-210 in BMSC-secreted exosomes improved angiogenesis by increasing the proliferation, migration, and tube formation capacity of HUVECs and contributed to cardiac protection. [83]
Mouse MI CXCL12, Nrf2 ADSCs EPC The exosomes from SIRT1-overexpressing ADSCs can restore the function of cell migration and tube formation and recruitment of EPCs to the repair area through Nrf2/CXCL12/CXCR7 signaling. [84]
Rat MI miR-21 EnMSCs HUVEC EnMSCs showed superior cardioprotection through angiogenic effects via the PTEN/Akt pathway. [73]
Rat MI miR-133a-3p hUC-MSCs HUVEC Exosomes from MIF-engineered hUC-MSCs enhanced proliferation, migration, and angiogenesis. [85]
Rat MI lncRNA H19 BMSCs HUVEC Exosomes from atorvastatin preconditioned MSCs can regulate the expression of miR-675 and activation of VEGF and intercellular adhesion molecule-1 to promote angiogenesis. [87]
Rat MI Sfrp2 hUC-MSCs HUVEC TIMP2-modified hUC-MSC-derived exosomes can promote HUVEC proliferation, migration, and tube formation in vitro and angiogenesis in rat MI model. [86]
Rat MI PDGF-D hUC-MSCs HUVEC Exosomes derived from Akt-modified hUC-MSCs resulted in more effective angiogenesis through PDGF-D secretion. [88]
Limited inflammation
Mouse I/R miRNA-181a hUCB-MSCs PBMC Overexpression of miRNA-181a in hUCB-MSC-derived exosomes suppressed inflammatory response in the PBMCs and promoted Treg cell polarization through targeting c-Fos. [91]
Mouse I/R miR-182 BMSCs Raw264.7 BMSC-derived exosomes mediated macrophage polarization by targeting toll-like receptor 4. [90]
Mouse MI LPS-primed exosomes BMSCs Raw264.7 Exosomes obtained from LPS preconditioning BMSCs strongly increased M2 macrophage polarization and attenuated the postinfarction inflammation in the MI model through inhibition of LPS-dependent NF-κB signaling pathway and activation of the AKT1/AKT2 signaling pathway. [92]
Vitro model miR-10a AD-MSCs Naïve T cells miR-10a-loaded exosomes from AD-MSCs facilitated Th17 and Treg responses while reduced that of Th1 in spleen-derived naïve T cells. [94]
Vitro model miR-34a, miR-124, and miR-135b AD-MSCs THP-1 Melatonin-stimulated exosomes derived from AD-MSCs promoted M2 macrophage differentiation and exerted superior anti-inflammatory response. [93]
Vitro model IDO hUC-MSCs PBMC Exosomes from TGF-β and IFN-γ-stimulated hUC-MSCs significantly promoted the transformation of mononuclear cells to Tregs through IDO regulation. [95]
Cardiac remodeling
Rat MI miR-29 and miR-24 BMSCs Fibroblast BJ cells BMSC-secreted exosomes enhanced cardiac repair by transferring miR-29 and miR-24 to fibroblasts. [17]
Rat MI Sfrp2 hUC-MSCs Fibroblast TIMP2-modified hUC-MSC-derived exosomes decreased TGF-β-induced MMP2, MMP9, and α-SMA secretion in cardiac fibroblasts and inhibit ECM remodeling. [86]
Vitro model miR-21, miR-23a, miR-125b, and miR-145 hUC-MSCs Fibroblast hUC-MSC-derived exosomes suppressed myofibroblast formation by inhibiting excess α-smooth muscle actin and collagen deposition via the activity of the TGF-β/SMAD2 signaling pathway. [102]

AD-MSCs: adipose mesenchymal stem cells; Mecp2: methyl CpG binding protein 2; HUVEC: human umbilical vein endothelial cells; VEGF: vascular endothelial growth factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; VEGF-R2 and VEGF-R3: receptors of vascular endothelial growth factor; MCP-2: monocyte chemoattractant protein 2; MCP-4: monocyte chemoattractant protein 4; PBMC: peripheral blood mononuclear cells; hUC-MSCs: human umbilical cord-derived mesenchymal stem cells; BMSCs: bone marrow mesenchymal stem cells; CTGF: connective tissue growth factor; NRCM: neonatal rat cardiac myocytes; MIF: macrophage migration inhibitory factor; EnMSCs: human endometrium-derived mesenchymal stem cells; PTEN: phosphatase and tensin homolog; ADRC: adipose-derived regenerative cells; CM: cardiomyocytes; I/R: ischemia-reperfusion; ADSCs: adipose-derived stem cells; HcBMSCs: hypoxia-conditioned bone marrow mesenchymal stem cells; AMI: acute myocardial infarction; ADSC-CM: adipose-derived stem cell conditioned medium; NMCM: neonatal mouse cardiomyocytes; hiPSC: human-induced pluripotent stem cell; EGR1: early growth response factor 1; Mecp2: methyl CpG binding protein 2; lncRNA: long noncoding RNA; hUCB-MSCs: human umbilical cord blood-derived MSCs; EPCs: endothelial progenitor cells; PDGF-D: platelet-derived growth factor D; CXCL12: C-X-C motif chemokine 12; Nrf2: nuclear factor E2 related factor 2; Sfrp2: secreted frizzled- (Fz-) related protein 2; TIMP2: tissue matrix metalloproteinase inhibitor 2; MMPs: matrix metalloproteinases; ceRNA: competitive endogenous RNA; LPS: lipopolysaccharide.